clinical trial · NCT02789345
A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer
Eli Lilly and Company·phase1·completed·n = 29
Non-small Cell Lung CancerRamucirumabNecitumumabOsimertinib
brief summary
The main purpose of this study is to evaluate the safety of ramucirumab or necitumumab in combination with osimertinib in participants with non-small cell lung cancer (NSCLC).
started
Oct 24, 2016
primary completion
Oct 19, 2017
completion
May 9, 2022
last updated
Feb 5, 2024
official title
An Open-Label, Multicenter, Phase 1 Study With Expansion Cohorts of Ramucirumab or Necitumumab in Combination With Osimertinib in Patients With Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer After Progression on First-Line EGFR TKI Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol